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It has been shown that 2,4-diamino-6-arylmethylpteridines
and 2,4-diamino-5-arylmethylpyrimidines containing an O-
carboxylalkyloxy group in the aryl moiety are potent and
selective inhibitors of the dihydrofolate reductase (DHFR)
from opportunistic pathogens such as Pneumocystis carinii, the
causative agent of Pneumocystis pneumonia in HIV/AIDS
patients. In order to understand the structure–activity proﬁle
observed for a series of substituted dibenz[b,f]azepine
antifolates, the crystal structures of mouse DHFR (mDHFR;
a mammalian homologue) holo and ternary complexes with
NADPH and the inhibitor 2,4-diamino-6-(20-hydroxy-
dibenz[b,f]azepin-5-yl)methylpteridine were determined to
1.9 and 1.4 A ˚ resolution, respectively. Structural data for the
ternary complex with the potent O-(3-carboxypropyl) inhi-
bitor PT684 revealed no electron density for the O-
carboxylalkyloxy side chain. The side chain was either cleaved
or completely disordered. The electron density ﬁtted the less
potent hydroxyl compound PT684a. Additionally, cocrystalli-
zation of mDHFR with NADPH and the less potent 20-(4-
carboxybenzyl) inhibitor PT682 showed no electron density
for the inhibitor and resulted in the ﬁrst report of a
holoenzyme complex despite several attempts at crystal-
lization of a ternary complex. Modeling data of PT682 in the
active site of mDHFR and P. carinii DHFR (pcDHFR)
indicate that binding would require ligand-induced conforma-
tional changes to the enzyme for the inhibitor to ﬁt into the
active site or that the inhibitor side chain would have to adopt
an alternative binding mode to that observed for other
carboxyalkyloxy inhibitors. These data also show that the
mDHFR complexes have a decreased active-site volume as
reﬂected in the relative shift of helix C (residues 59–64) by
0.6 A ˚ compared with pcDHFR ternary complexes. These data
are consistent with the greater inhibitory potency against
pcDHFR.
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1. Introduction
Antifolates have been shown to be effective against dihydro-
folate reductase (DHFR) from opportunistic pathogens such
as Toxoplasma gondii (tg) and Pneumocystis carinii (pc), the
causative agent of Pneumocystis pneumonia (PcP), which is
still a cause of mortality among immunocompromised patients
such as those with HIV/AIDS (Kovacs et al., 2002; Thomas &
Limper, 2004; Wakeﬁeld, 2002). The antifolate trimethoprim
(TMP; Fig. 1), when used in combination with sulfamethox-azole, synergistically targets the folate synthesis of these
pathogens and is currently the preferred treatment for PcP
(Stringer et al., 2002; Cushion et al., 2004). However, TMP has
limited efﬁcacy and drug resistance to TMP treatment is
becoming more prevalent (Medrano et al., 2005). These data
illustrate the need for continued efforts to design more
selective and potent inhibitors against these opportunistic
infectious pathogens.
Recent structure activity data have shown that dibenz-
[b,f]azepines such as PT653 (Fig. 1) are moderately selective
against pcDHFR and have a 100-fold increased binding
preference for tgDHFR (Rosowsky et al., 1999). These studies
led to the structure-based design of a series of 2,4-diamino-
6-[(!-carboxyalkyl)oxy]dibenz[b,f]azepin-5-yl]pteridines that
were more potent and selective than trimethoprim as inhibi-
tors of DHFR from such opportunistic pathogens as P. carinii,
T. gondii or Mycobacterium avium (Rosowsky et al., 2004;
Chan et al., 2005). As illustrated in Table 1, these data revealed
that the 20-O-(3-carboxypropyl) analogue (PT684; Fig. 1) had
the greatest inhibitory potency against pcDHFR, with an IC50
of 1.1 nM and a selectivity ratio of 1363 when compared with
rat DHFR. Similarly, the 20-O-(4-carboxybenzyl) analogue
(PT682; Fig. 1) showed signiﬁcant potency with an IC50 of
1.0 nM against pcDHFR, but had lower selectivity against the
pathogenic DHFR and showed a selectivity ratio of 580 when
compared with rat DHFR (Rosowsky et al., 2004). These data
suggest that modiﬁcation of the 20-position of the dibenz[b,f]-
azepine ring contributes signiﬁcantly to deﬁning selectivity for
the pathogenic DHFR enzymes. Computational models of the
binding of the potent dibenz[b,f]azepine PT684 to human
DHFR and pcDHFR has been carried out in order to better
understand the selectivity proﬁles observed for this class of
inhibitors (Rosowsky et al., 2004). The crystal structures of the
parent antifolate PT653 (Fig. 1) bound to pcDHFR (Cody et
al., 2002) and the tight-binding inhibitor PT523 (Fig. 1; Cody et
al., 1997) were used as starting models for these calculations.
The results revealed a model in which the inhibitor carbox-
ylate interacted with the conserved Arg in the active site,
similar to that observed for other O-carboxyalkyloxy inhibi-
tors (Cody et al., 2006). These data suggested that differences
in the interactions between the carboxylate of the inhibitor
and Lys37 in pcDHFR and Gln35 in
hDHFR could contribute to their
enhanced selectivity for pcDHFR.
Based on the observations that the
active-site residues of the mammalian
DHFRs are highly conserved and that
mouse DHFR (mDHFR) was easier to
crystallize than human DHFR, we
carried out structural studies using
mouse DHFR. To better understand the
mechanism of selectivity in binding to
pcDHFR, the crystal structures of
PT684 and PT682 were determined in
complex with mouse DHFR and are
compared with that of the parent
benz[b,f]azepine PT653 (Fig. 1; Cody et
al., 2002). Efforts are also under way to
crystallize these inhibitors with
pcDHFR.
2. Methods
2.1. Expression of wild-type mDHFR
Recombinant mDHFR was ex-
pressed and puriﬁed as described
previously (Pineda et al., 2003). A single
colony of Escherichia coli JM105 cells
containing the pPH70D plasmid that
harbors the fusion product of E. coli
L54F DHFR and mDHFR linked with
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Table 1
Enzyme inhibition (IC50 in nM) against DHFR for selected inhibitors
(Fig. 1; Chan et al., 2005; Rosowsky et al., 2004).
Inhibitor pcDHFR Rat DHFR
Rat DHFR/pcDHFR
selectivity ratio
TMP 13000 180000 13.8
PTX 13 3.3 0.26
PT684 1.1 1500 1363
PT682 1.0 580 580
PT684a 31 14 1.3
PT653 79 3000 37.9
Figure 1
Schematic representations of the antifolates under study.thrombin was used to inoculate a 10 ml culture of Luria–
Bertani (LB) broth (25 g l
 1) containing 50 mgm l
 1 ampi-
cillin. After incubation at 310 K overnight with shaking, one
10 ml culture was used to inoculate a 1 l culture of LB broth
containing 50 mgm l
 1 ampicillin. Bacteria were grown to an
OD600 of 0.4–0.6, after which expression of mDHFR was
induced by the addition of isopropyl  -d-1-thiogalactoside
(IPTG) to a ﬁnal concentration of 1 mM. After an induction
time of 3 h, the cells were harvested by centrifugation at 277 K
and 7000g for 30 min. The cell pellets were resuspended in
12.5 ml lysis buffer A (50 mM Tris, 5 mM EDTA, 50 mgm l
 1
NaN3, 10 ml protease-inhibitor cocktail pH 8.0) per gram of
wet cells. The solution was left to incubate for 10 min at room
temperature on a stir plate. 1.5 ml lysis buffer B (1.5 M sodium
chloride, 0.1 M calcium chloride, 20 mgm l
 1 DNase, 1 mM
PMSF) per gram of wet cells was added. The solution was
incubated for 10 min at room temperature on a stir plate.
Dithiothreitol (DTT) was added to a ﬁnal concentration of
5m M. The sample was then subjected to six cycles of ultra-
sonic cell disruption for 15 s with intermittent cooling periods
of 30 s on ice. The clariﬁed supernatant was obtained by
centrifugation at 277 K and 12 000 rev min
 1 for 30 min.
2.2. Purification of mDHFR
The supernatant was dialyzed into PE buffer (20 mM
potassium phosphate, 1 mM EDTA, 1 mM DTT pH 7.4). The
protein was loaded at 0.5 ml min
 1 onto a DEAE column
equilibrated with PE buffer. The column was washed with
50 ml PE buffer with 1 mM DTT. The fusion protein,
containing both E. coli DHFR L54Fand mDHFR joined by a
thrombin linker, was eluted with an 800 ml gradient of 0–0.5 M
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Table 2
Data-collection and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
PT684a–NADPH NADPH
Data collection
Space group P21 P21
Unit-cell parameters (A ˚ ,  ) a = 41.48,
b = 61.30,
c = 43.59,
  = 117.22
a = 41.23,
b = 61.17,
c = 43.15,
  = 118.26
Source SSRL 9-1 R-AXIS IV
Resolution (A ˚ ) 1.00 1.90
Wavelength (A ˚ ) 1.00 1.5418
Rmerge 0.083 (1.08) 0.034 (0.076)
Rsym† (%) 0.100 (1.49) 0.051 (0.48)
Completeness (%) 98.3 (97.4) 90.7 (50.5)
Observed reﬂections 38237 14951
Unique reﬂections 35455 13551
I/ (I) 7.3 (0.7) 13.3 (2.5)
Multiplicity 3.4 (2.0) 15.1 (3.4)
Reﬁnement and model quality
Resolution range (A ˚ ) 31.61–1.40 23.83–1.90
No. of reﬂections 35455 12865
R factor‡ 19.8 18.6
Rfree§ 21.3 21.0
Total protein atoms 1665 1665
Total ligand atoms 76 60
Total water atoms 319 82
Average B factor (A ˚ 2) 19.7 19.0
R.m.s. deviation from ideal
Bond lengths (A ˚ ) 0.011 0.018
Bond angles ( ) 1.682 2.060
Ramachandran plot, residues in
Most favored regions (%) 91.8 93.7
Additional allowed regions (%) 8.2 6.3
Generously allowed regions (%) 0.6 1.1
Disallowed regions (%) 0.0 0.0
PDB code 3d80 3d84
† Rsym =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where hI(hkl)i is the mean
intensity of a set of equivalent reﬂections. ‡ R factor =
P
jFobs   Fcalcj=
P
Fobs, where
Fobs and Fcalc are observed and calculated structure-factor amplitudes. § Rfree was
calculated as the R factor for a random 5% subset of all reﬂections.
Figure 2
(a) Difference electron density (2Fo   Fc,1 . 0  ) showing the inhibitor
PT684a as a ternary complex with NADPH in mDHFR. Also shown are
two alternate conformations for Phe31. (b) Difference electron density
(Fo   Fc,3  ) from an OMIT map calculated from the ﬁnal reﬁnement
without inhibitor present. There is no indication of a partially occupied
inhibitor side chain.KCl. Fractions were monitored (Blakley, 1960) and those
containing DHFR activity were pooled, concentrated using a
YM-30 membrane and dialyzed into thrombin cleavage buffer
(50 mM Tris, 0.1 M NaCl, 2.5 mM CaCl2 pH 8.0). Cleavage of
the fusion protein was initiated by the addition of 5 units of
thrombin per milligram of fusion protein. The sample was left
to incubate overnight (15–18 h) at 277 K. The next day, the
protein was dialyzed for >3 h back into PE buffer containing
freshly added DTT at 1 mM ﬁnal concentration. The protein
was then loaded onto a DEAE (GE Bioscience) column pre-
equilibrated with PE buffer containing 1 mM DTT at
0.5 ml min
 1. After washing the column with 50 ml PE buffer
containing 1 mM DTT, the cleaved mDHFR was eluted from
the column using a 600 ml gradient of 0–0.1 M KCl. Fractions
containing DHFR activity were pooled and concentrated
using a YM10 membrane.
2.3. Crystallization
The protein was washed in a Centricon-10 with 10 mM
HEPES buffer pH 7.4, concentrated to 27 mg ml
 1 and incu-
bated with NADPH and a 10:1 molar excess of the inhibitors
2,4-diamino-6-{20-O-(3-carboxylpropyl)oxydibenz[b,f]azepin-
5-yl}methylpteridine (PT684) or 2,4-diamino-6-{20-O-(4-car-
boxybenzyl)oxydibenz[b,f]azepin-5-yl}methylpteridine (PT682)
for 1 h over ice prior to crystallization using the hanging-drop
vapor-diffusion method. Protein droplets contained 0.15 M
Tris pH 8.3, 75 mM sodium cacodylate, 21% PEG 4K for the
PT684 complex and 10 mM HEPES pH 7.4,
17 mM sodium acetate pH 6.5, 85 mM Tris–
HCl and 25% PEG 4K for the PT682
complex. Crystals grew over several weeks
and were treated with 15% glycerol as a
cryoprotectant prior to mounting in the cold
stream. The crystals of both complexes are
monoclinic, space group P21, and diffracted
to 1.4 and 1.9 A ˚ resolution for PT684 and
PT682, respectively. Data for the complex
with PT684 were collected on beamline 9-1
at the Stanford Synchrotron Resource
Laboratory (SSRL) using the remote-access
protocol (McPhillips et al., 2002; Cohen et
al., 2002; Gonza ´lez et al., 2008) and data for
the PT682 complex were collected on a
Rigaku R-AXIS IV imaging-plate system
with MaxFlux optics. Data were processed
using both DENZO (Otwinowski & Minor,
1997) and MOSFLM (Collaborative Com-
putational Project, Number 4, 1994).
Diffraction statistics are shown in Table 2
for both complexes.
2.4. Structure determination
The structures were solved by molecular-
replacement methods using the coordinates
of mDHFR (PDB code 2fzj; Cody et al.,
2006) in the program MOLREP (Collab-
orative Computational Project, Number 4,
1994). To monitor the reﬁnement, a random
subset of all reﬂections was set aside for the
calculation of Rfree (5%). Inspection of the
resulting difference electron-density maps
was made using the program Coot (Emsley
& Cowtan, 2004) running on a Mac G5
workstation. The structures of the inhibitors
were modeled based on those of PT653
(Fig. 1) reported in the structure of
pcDHFR (Cody et al., 2002) using the
builder function in SYBYL (Tripos, St Louis,
Missouri, USA) and the parameter ﬁles for
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Figure 3
Stereoview of the ternary complex of NADPH and PT684a with mDHFR. The active-site
residues Glu30, Gln35, Ser59, Asn64 and Arg70 are shown. This ﬁgure was drawn with
PyMOL.
Figure 4
Stereoview of the conserved Arg70 interactions with their contact distances for the mDHFR–
PT684a–NADPH ternary complex. This ﬁgure was drawn with PyMOL.the inhibitors were prepared using the Dundee PRODGR2
server website (http://davapc1.bioch.dundee.ac.uk/programs/
prodrg; Schu ¨ettelkopf & van Aalten, 2004). The ﬁnal cycles of
reﬁnement were carried out using the program REFMAC5
from the CCP4 suite of programs (Collaborative Computa-
tional Project, Number 4, 1994). The Ramachandran confor-
mational parameters from the last cycle of reﬁnement
generated by PROCHECK (Laskowski et al., 1993) showed
that more than 90% of the residues in both mDHFR
complexes have the most favored conformation and that none
are in disallowed regions. Coordinates for this structure have
been deposited in the Protein Data Bank (PDB codes 3d80
and 3d84). Figures were prepared using the modeling program
PyMOL (DeLano, 2006).
3. Results
3.1. mDHFR ternary complex
Inspection of the difference electron-density map for the
ternary complex of mDHFR with NADPH and what was
initially assumed to be the carboxylic acid PT684 revealed no
electron density for the 4-carboxypropyl side chain (Fig. 2). It
is unclear whether the side chain is completely disordered in
this region or whether the sample had decomposed on storage
or on crystallization. One other possibility is that intra-
molecular catalysis had resulted in spontaneous cleavage of
the carboxypropyl side chain during storage or under the
crystallization conditions used, so that the molecule actually in
the active site was the 2-hydroxydibenzazepine PT684a
(Fig. 3). The side chains of Phe31 and Gln35 were also
observed in two alternate conformations in this complex.
There is a partial water molecule present in one of the Gln35
conformers that also contacts Arg70 when the partially
occupied Gln35 is not present.
The more surprising observation for these data is the lack of
involvement of the putative hydroxyl group of PT684a in any
hydrophilic interactions. The closest contact of the hydroxyl
group of PT684a is with a partially occupied conformer of
Phe31 (2.9 A ˚ ), while the other contact distances range from
3.7 to 4.7 A ˚ to the partially occupied water/Gln35 and the side
chains of Asn64 and Leu60 (Fig. 4).
As previously described in the structures of mDHFR–
inhibitor complexes (Cody et al., 2005, 2006; Cody & Schwalbe,
2006), the orientation of the conserved
Arg70 is held in place by a network of
hydrogen bonds with the conserved Thr38
and Thr39 and the backbone functional
groups of Lys68 and through water to the
backbone carbonyl of Asn64. There are also
contacts to other structural water molecules
in the active pocket (Fig. 4).
3.2. mDHFR holoenzyme complex
When the difference density maps were
analyzed for the complex with PT682, it was
shown that the ﬁnal structure is a holo-
enzyme complex containing only the
cofactor NADPH (Fig. 5). Although
diffraction data from three separate crys-
tallization trials were collected, all crystals
were found to be holoenzyme complexes.
This is the ﬁrst report of a mammalian
DHFR holo complex structure. The active
site is occupied by a molecule of glycerol
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Figure 5
Difference electron density (2Fo   Fc,1  ) for the holo complex with
cofactor NADPH in mDHFR. The density in the active site was ﬁtted to
glycerol from the cryoprotection buffer.
Figure 6
Stereoview of mDHFR with NADPH and a glycerol molecule in the active site of the holo
structure. Residues Glu30, Gln35, Asn64 and Arg70 are shown. This ﬁgure was drawn with
PyMOL.used as a cryoprotection agent during diffraction data
collection (Fig. 6).
3.3. Overall structure
There are no signiﬁcant changes in the overall structure of
the holo and ternary mDHFR complexes (r.m.s.d. = 0.38 A ˚
between all residues in these two structures), which also are
similar to previously reported mDHFR structures (Cody et al.,
2005, 2006). The interactions of the 2,4-diaminopteridine ring
of PT684a preserves the overall pattern of contacts with
invariant residues in the active site as observed in other
DHFR–inhibitor complexes (Cody & Schwalbe, 2006). The
intermolecular interactions of PT684a are also similar to those
observed for the parent compound PT653 reported in the
crystal structure with pcDHFR (Cody et al., 2002; Fig. 7); the
4-amino group makes a number of hydrogen-bond contacts
with the backbone functional groups of Ile7 (2.9 A ˚ ) and
Val115 (3.1 A ˚ ) and the side chains of Tyr121 (3.4 A ˚ ) and the
nicotinamide of NADPH (3.5 A ˚ ) that contribute to the tight
binding of antifolates. There is an invariant hydrogen-bond
network involving structural water, the conserved residues
Thr136, Glu30 and Trp24 and the N1 nitrogen and 2-amino
group of PT684a. The pteridine ring N8 makes contacts to
Glu30 and Trp24 through a structural water molecule that is
observed in most DHFR structures.
Comparison of these mDHFR complexes with those of the
parent PT653 bound to pcDHFR (Cody et al., 2002) and with
methotrexate (MTX) bound to mouse and
human DHFR (Cody et al., 2006) reveals
that the backbone of helix C (encompassing
residues 59–64; human numbering) is
displaced by 0.2–1.3 A ˚ depending on the
ligand bound and reﬂects ligand-induced
conformational changes (Cody et al., 1999).
Measurements of the distances between the
C
  atom of residue Glu30 and the C
  atoms
of residues Asp21, Leu22, Ser59 and Leu60
(Table 3) describe the relative size of the
active site in these structures. As illustrated,
the largest differences measured at positions
59 and 60 are between the human DHFR–
MTX complex (Cody et al., 2005) and the
pcDHFR–PT653 complex (Cody et al., 2002)
with a shift of 1.3 A ˚ in the relative position
of helix C, making the pcDHFR active site
larger as a result of ligand-induced confor-
mational changes (Cody et al., 1999; Fig. 8).
The difference between the helix C positions
of mDHFR–PT684a and hDHFR–MTX is
0.7–1.3 A ˚ . It is somewhat surprising to note
that there is little change in these contact
distances between the holo and PT684a
ternary complex with mDHFR (Table 3).
These data suggest that the MTX ternary
complexes are more tightly bound and that
the human enzyme has the smallest active-
site volume.
4. Discussion
These structural studies describe the binding
of a hydrolyzed product PT684a (Fig. 1) as a
ternary complex with NADPH and
mDHFR; no electron density was evident
for the carboxyalkyloxy side chain. There
was also no evidence of a partially occupied
position for the side chain. These observa-
tions suggest that the side chain is comple-
tely disordered or has been cleaved under
the storage or crystallization conditions
research papers
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Figure 7
Stereo superposition of the mDHFR ternary complex with PT684a (green) and the pcDHFR
(cyan) ternary complex with NADPH and inhibitor PT653 (Cody et al., 2002). The mDHFR
sequence numbers are shown for the active-site residues. This ﬁgure was drawn with PyMOL.
Figure 8
Stereo comparison of mDHFR–NADPH–PY684a (green), hDHFR–MTX–NADPH (Cody et
al., 2005; cyan) and pcDHFR–NADPH–PT653 (Cody et al., 2002; violet), highlighting the
conformation of loop 21 and helix C with residues Ser59 and Leu60 in all structures. Residues
are numbered for the mammalian enzyme. Position 21 isAsp in the mammalian DHFR and Ser
in pcDHFR, 22 is Leu in all structures, 30 is Glu in all three structures and 31 is Phe in
mammalian and Ile in pcDHFR. This ﬁgure was drawn with PyMOL.used, resulting in density that is consistent with the hydroxyl
compound PT864a. This product was shown to be less potent
(Table 1) than those that contain a carboxylate side chain that
can interact with the conserved Arg70 present in all DHFRs.
Comparison of this complex with the parent dibenz[b,f]aze-
]azepine PT653 (Cody et al., 2002; Fig. 7) reveals only small
variations in the buckling of the dibenz[b,f]azepine ring
compared with the mDHFR complex.
One of the strategies developed for the design of these
dibenz[b,f]azepine antifolates was to probe the binding
interactions in the ﬂexible loop near residues 20–24 of the
DHFR active site. Thus, by making a rigid group that could
occupy this region while still occupying the p-aminobenzoyl
glutamate portion of the substrate active-site pocket, it would
be possible for this rigid group to exploit differences in the
active-site volume that result from movement of the ﬂexible
loop 20–24 between the mammalian and fungal DHFR
enzymes (Rosowsky et al., 1999). Comparison of the loop 20–
24 positions in the structures of the human, mouse and
P. carinii DHFR complexes with MTX and the dibenz[b,f]-
azepine antifolates reveals that the greatest difference is
between the hDHFR–MTX complex and the mDHFR
complex with PT684a, as measured by the differences in the
distance from the C
  atom of Glu30 to those of Asp21 and
Leu22 (Table 3, Fig. 8). These data reveal a progressive
increase in the distance for the pcDHFR–MTX, pcDHFR–
PT653 and mDHFR–PT684a ternary complexes, respectively.
It is somewhat surprising that the mDHFR holoenzyme
complex has the same contact distances as the PT684a ternary
complex.
Similarly, the effects of ligand-induced conformational
changes are reﬂected in the relative movement of helix C
(residues 59–64), which indicates an increase in the active-site
size among these species. However,in this case the largest shift
is observed for the PT653 ternary complex with pcDHFR,
which has a 1.3 A ˚ displacement at residue Leu60 of helix C
relativetothehumanDHFR–MTXternary complex(Table3).
The change for the mDHFR ternary complex with PT684a is
0.7 A ˚ relative to the 0.4 A ˚ difference for the pcDHFR–MTX
complex.
These data also show that the complex with the highly
selective inhibitor PT682 resulted in the ﬁrst report of a
mammalian holo mDHFR enzyme complex with the cofactor
NADPH. Despite efforts to cocrystallize PT682 as a ternary
complex with mDHFR, only the holoenzyme complex was
observed. Modeling studies of the binding of PT682 to
mDHFR and pcDHFR indicate that an alternate binding
mode is needed for this inhibitor to ﬁt into the active site. If in
both mDHFR and pcDHF the binding of PT682 is similar to
that observed for PT653 in pcDHFR (Cody et al., 2002), then
the carboxylate side chain has steric clashes with the
conserved Arg in the active site (Fig. 9). The fact that PT684
has signiﬁcant potency and selectivity in pcDHFR would
suggest that ligand-induced conformational changes need to
occur for inhibitor binding or that the carboxyalkyloxy side
chain can adopt an alterative conformation and forgo
interaction with Arg, as observed in other carboxyalkyloxy
inhibitors (Cody et al., 2006). These data may indicate that the
steric bulk of this antifolate is such that it is prevented from
binding to any signiﬁcant degree in mDHFR. These models
for the binding of PT682 are in contrast to
those derived for the binding of PT684, in
which the carboxylate was shown to interact
with the conserved Arg in both pcDHFR
and hDHFR (Rosowsky et al., 2004). These
data are the ﬁrst to illustrate the lack of
binding to mammalian DHFR to explain
its loss of potency compared with
pcDHFR.
Crystallization screens are under way to
obtain complexes of pcDHFR with the
potent dibenz[b,f]azepine antifolates PT684
and PT682 in order to validate the compu-
tational models that suggested that inter-
actions of the 20-(!-carboxyalkyloxy) or 20-
(4-carboxybenzyloxy) substitutent with the
conserved active-site Arg70 and the differ-
ential interactions with Gln35 in mammalian
versus Lys37 in pcDHFR contribute to their
high potency and selectivity against the
pathogenic DHFR enzymes.
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Figure 9
Stereo comparison of the ternary complex of mDHFR with NADPH and PT684a (green),
pcDHFR with PT653 (cyan; Cody et al., 2002) and a model of PT682 (yellow). Note that the
carboxylate group clashes with Arg70.
Table 3
Contact distances (A ˚ ) between active-site residues in DHFR complexes.
Residue C
 
30   22 30   21 30   59 30   60
mDHFR–PT684a 12.2 15.1 17.5 15.3
Holo mDHFR 12.3 15.3 17.2 15.3
mDHFR L22R–MTX† 12.1 14.5 16.5 14.8
hDHFR–MTX† 12.2 14.7 16.2 14.6
pcDHFR–PT653‡ 12.3 15.1 17.9 15.9
pcDHFR–MTX§ 11.7 15.0 16.5 14.7
† Cody et al. (2005). ‡ Cody et al. (2002). § Cody et al. (1999).This work was supported in part by grants from the
National Institutes of Health GM51670 (VC). The authors
thank the beamline 9-1 staff at SSRL for their support.
Portions of this research were carried out at the Stanford
Synchrotron Radiation Laboratory, a national user facility
operated by Stanford University on behalf of the US
Department of Energy, Ofﬁce of Basic Energy Sciences. The
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